BIOMAT Database Logo BIOMAT Database Logo

Evaluation in children of cold-adapted influenza B live attenuated intranasal vaccine prepared by reassortment between wild-type B/Ann Arbor/1/86 and cold-adapted B/Leningrad/14/55 viruses. 1990

N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Ivanovsky Institute of Virology, Academy of Medical Sciences, Moscow, USSR.

A reassortant cold-adapted (ca) influenza B experimental live attenuated intranasal vaccine was evaluated for safety and immunogenicity in children by means of a blind, placebo controlled study. The vaccine contained the haemagglutinin and neuraminidase genes, and the gene for its non-structural proteins from wild-type (wt) B/Ann Arbor/1/86 virus, the contemporary strain at the time of the study. Other genes were derived from ca B/Leningrad/14/55 virus. No increase in illness rates was seen in the children from ages 3-15 years given vaccine at maximum potency (a one in two dilution of infectious allantoic fluid, having a titre of 10(7.0) EID50) compared to children given placebo. About 60% of seronegative children, ages 3-7 years, exhibited a detectible antibody response following one dose of intranasal vaccine, with the seroresponse rate rising to greater than 70% after two doses of vaccine. Immunogenicity was lowest in seropositive children age 8-15 years, reaching a maximum of 36% after two doses. Results indicated that the vaccine was highly attenuated, and probably of adequate immunogenicity for kindergarten age children. The lower immunogenicity in older children suggests the vaccine might be overly attenuated for use in school-age children who are more likely to have a history of prior natural infection with influenza B virus. Further clinical and epidemiological studies of protection are needed to fully assess this.

UI MeSH Term Description Entries
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D009981 Influenza B virus Species of the genus BETAINFLUENZAVIRUS that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed. Betainfluenzavirus influenzae,FLUBV,Human Influenza B Virus,Influenza Viruses Type B,Influenza virus type B,Orthomyxoviruses Type B,Influenza B viruses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006385 Hemagglutination Inhibition Tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination. Hemagglutination Inhibition Test,Inhibition Test, Hemagglutination,Inhibition Tests, Hemagglutination,Test, Hemagglutination Inhibition,Tests, Hemagglutination Inhibition
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children.
April 1991, The Journal of infectious diseases,
N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Intranasal, cold-adapted, live, attenuated influenza vaccine.
December 1999, The Pediatric infectious disease journal,
N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers.
May 1990, The Journal of infectious diseases,
N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates.
February 1990, Vaccine,
N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Cold-adapted, live attenuated intranasal influenza virus vaccine.
March 2003, The Pediatric infectious disease journal,
N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Sequence comparison of wild-type and cold-adapted B/Ann Arbor/1/66 influenza virus genes.
April 1988, Virology,
N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.
November 2012, Expert review of vaccines,
N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Genetic Basis of Attenuation of Cold-Adapted Influenza Strain B/Leningrad/14/17/55 - Backup Master Donor Virus for Influenza Type B Live Attenuated Vaccines.
March 2020, Bulletin of experimental biology and medicine,
N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Infant rat model of attenuation for recombinant influenza viruses prepared from cold-adapted attenuated A/Ann Arbor/6/60.
November 1982, Infection and immunity,
N P Obrosova-Serova, and A N Slepushkin, and A P Kendal, and M W Harmon, and E I Burtseva, and N I Bebesheva, and A L Beljaev, and N I Lonskaja, and T E Medvedeva, and A Y Egorov
Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2).
December 1988, Virology,
Copied contents to your clipboard!